Integra LifeSciences (NASDAQ:IART) Announces Quarterly Earnings Results

Integra LifeSciences (NASDAQ:IART) issued its quarterly earnings results on Wednesday. The life sciences company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08, FiscalAI reports. Integra LifeSciences had a positive return on equity of 18.31% and a negative net margin of 0.44%.The business had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences updated its Q3 2026 guidance to 0.530-0.610 EPS and its FY 2026 guidance to 2.400-2.500 EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

• Second-quarter execution improved: Revenue reached $419 million, up 0.7% organically, while adjusted EPS rose 24% year over year to $0.56 and exceeded the company’s guidance range. Gross margin expanded 60 basis points and adjusted EBITDA margin increased 160 basis points, supported by manufacturing efficiencies, lower remediation spending, and cost initiatives.
• Integra reaffirmed its 2026 organic revenue growth outlook of 0.8%-3.3% and adjusted EPS guidance of $2.40-$2.50, but lowered reported revenue expectations to $1.654-$1.695 billion because of foreign-ex exchange impacts. Potentially higher second-half interest expense from a planned refinancing is expected to be offset by tariff benefits and additional cost savings.
• Supply and product-relaunch milestones advanced: Manufacturing restarted at the Braintree facility, with inventory being built for a phased fourth-quarter SurgiMend relaunch. PriMatrix revenue has recovered to slightly above 50% of pre-recall levels, while DuraSorb continues to deliver double-digit growth.
• The company expects longer-term growth from potential PMA approvals for SurgiMend and DuraSorb in implant-based breast reconstruction, with SurgiMend targeted for earlier 2027 and DuraSorb later in 2027, subject to FDA inspections and approval.
• Tissue Reconstruction revenue declined 2% organically in the quarter, with Integra Skin facing a difficult comparison and MicroMatrix pressured by new competitors. ENT revenue also fell by low single digits as sinus-balloon reimbursement pressure outweighed growth in MicroFrance instruments.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART traded down $0.47 during mid-day trading on Friday, reaching $16.64. The stock had a trading volume of 402,053 shares, compared to its average volume of 909,888. The business’s 50 day moving average price is $17.67 and its 200 day moving average price is $13.45. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $20.49. The company has a market cap of $1.29 billion, a P/E ratio of -184.86, a price-to-earnings-growth ratio of 1.14 and a beta of 1.22. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Thursday, June 18th. BMO Capital Markets began coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective on the stock. Wall Street Zen cut shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Truist Financial increased their price target on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $18.86.

Institutional Trading of Integra LifeSciences

Hedge funds have recently modified their holdings of the company. Rubric Capital Management LP boosted its position in shares of Integra LifeSciences by 58.4% during the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock valued at $90,233,000 after acquiring an additional 2,710,262 shares during the last quarter. Paradigm Capital Management Inc. NY increased its position in Integra LifeSciences by 57.5% in the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock worth $26,767,000 after purchasing an additional 796,300 shares during the last quarter. Kotler Kevin purchased a new stake in Integra LifeSciences during the fourth quarter valued at $5,309,000. Soleus Capital Management L.P. raised its stake in Integra LifeSciences by 29.4% during the second quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company’s stock valued at $17,029,000 after purchasing an additional 315,614 shares in the last quarter. Finally, J. Goldman & Co LP lifted its position in Integra LifeSciences by 30.8% during the fourth quarter. J. Goldman & Co LP now owns 1,243,772 shares of the life sciences company’s stock valued at $15,448,000 after purchasing an additional 292,961 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.